An Early Signal of Promise in Gene Silencing for Obesity
January 7, 2026 — While all eyes in obesity focused on the launch of a daily oral tablet for ongoing treatment, Arrowhead Pharmaceuticals brought us a little surprise yesterday. They presented early data from phase one studies of two gene silencing therapies for obesity. Though these data are quite preliminary, they offer a signal of great promise for a […]
